Search filters

List of works by Fotios Loupakis

"HER majesty's a pretty nice girl but she changes from day to day".

scientific article

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer

scientific article published on 19 December 2015

A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.

scientific article published on 7 October 2008

A perspective on the current management of advanced colorectal cancer

scientific article published in November 2013

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

scientific article published on 25 March 2008

A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab

scientific article published on 5 December 2017

AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3

scientific article published on 26 March 2019

Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases

scientific article published on 14 June 2013

Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.

scientific article published on 23 November 2011

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.

scientific article published on 27 April 2016

Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.

scientific article

Are Dose-Finding Studies Still Necessary When Targeted Therapy Is Associated With Chemotherapy?

scientific article published on 01 October 2006

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

scientific article published on 09 October 2015

Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases

scientific article published on 06 September 2018

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.

scientific article

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

scientific article published on 7 July 2015

BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling

scientific article

BRAF-mutated metastatic colorectal cancer between past and future.

scientific article published on 10 September 2015

Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.

scientific article

Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle

scientific article published on 01 August 2011

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

scientific article published on 9 August 2010

Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer

scientific article

Biomarkers and response to bevacizumab--letter

scientific article published on 01 February 2014

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

scientific article

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy

scientific article published on 9 August 2016

Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers.

scientific article

Cancer dormancy: a model of early dissemination and late cancer recurrence.

scientific article published on 09 December 2011

Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis

scientific article

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

scientific article published on 8 July 2010

Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?

scientific article published in April 2010

Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients.

scientific article

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients

scientific article published on 23 May 2010

Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.

scientific article published on 15 March 2012

Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases

scientific article published on 25 June 2019

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

scientific article published on 25 August 2011

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers

scientific article published on 2 March 2012

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.

scientific article published on 17 November 2015

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

scientific article

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

scientific article published on 18 January 2015

Correction to: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases

scientific article published on 24 September 2019

Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer.

scientific article published on 27 January 2011

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.

scientific article published on 21 December 2017

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

scientific article published on 06 February 2019

Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients

scientific article

Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.

scientific article published on 23 December 2014

Do we need biopsies of metastases for colorectal cancer patients?

scientific article published on 7 July 2009

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.

scientific article published on 3 July 2013

EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle

scientific article published on 01 March 2012

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

scientific article published on 23 February 2015

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

scientific article published on 13 December 2016

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

scientific article published on 27 August 2009

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.

scientific article

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

scientific article published on 01 July 2015

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

scientific article published on 10 July 2014

FOLFOXIRI and bevacizumab for metastatic colorectal cancer

scientific article published on 01 January 2015

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

scientific article published on 10 May 2013

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.

scientific article published on 9 February 2016

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

scientific article published on 15 October 2013

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

scientific article

First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer

scientific article published on 09 June 2006

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

scientific article published on 5 June 2015

First-line chemotherapy for mCRC—a review and evidence-based algorithm.

scientific article published on 28 July 2015

Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.

scientific article published on 11 June 2013

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

scientific article published on 27 February 2018

Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.

scientific article published on 29 July 2014

Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan

scientific article

Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.

scientific article

Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.

scientific article published in March 2016

High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice

scientific article published on 01 July 2010

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

scientific article published on 04 December 2008

High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease

scientific article

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.

scientific article published on 23 May 2013

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.

scientific article published on 15 March 2017

Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy.

scientific article published in September 2010

Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

scientific article published on 01 January 2010

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials

scientific article published on 2 August 2017

Influence of sex on the survival of patients with esophageal cancer.

scientific article

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

scientific article

Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.

scientific article published in October 2010

Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer

scientific article published on 9 December 2014

Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis

scientific article published on 09 April 2020

KRAS and BRAF genotyping of synchronous colorectal carcinomas

scientific article

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

scientific article published on 14 July 2009

Liquid biopsy: monitoring cancer-genetics in the blood

scientific article

Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases

scientific article published in March 2009

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

scientific article published on 26 May 2010

Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer

scientific article published on 9 November 2015

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients

scientific article published on 9 March 2018

New perspectives for TAS-102: TASK successful?

scientific article published on 28 July 2017

Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy

article

Optimal approach to potentially resectable liver metastases from colorectal cancer

scientific article published on 01 October 2008

Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology

scientific article published on 2 July 2015

Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.

scientific article

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

scientific article published on 01 March 2012

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

scientific article published on 27 April 2009

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

scientific article

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer

scientific article

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy

scientific article published on 01 April 2007

Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients

scientific article published on 27 February 2018

Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction

scientific article published on 5 November 2008

Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.

scientific article published on 17 March 2010

Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.

scientific article

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer

scientific article

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.

scientific article

Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes

scientific article published on 22 January 2020

Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?

scientific article published on 22 February 2010

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

scientific article

Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer.

scientific article

Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States ⬇️

scientific article published on 05 August 2013

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

scientific article published on 14 March 2018

Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study

scientific article published on 08 June 2018

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management

scientific article published on 17 August 2015

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

scientific article published on 19 August 2015

Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients

scientific article

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab

scientific article

Publisher Correction: Shared heritability and functional enrichment across six solid cancers

scientific article published on 23 September 2019

QoL is a cool tool.

scientific article published on 18 April 2017

Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.

scientific article published on 5 May 2016

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.

scientific article

Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.

scientific article published in November 2009

Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'

scientific article published on 24 October 2013

Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

scientific article published on 16 February 2010

Response

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

scientific article

Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.

scientific article

Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.

scientific article

Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies

scientific article published on 01 February 2019

Selecting the best targeted agent in first‐line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers? ⬇️

scientific article published on September 1, 2012

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

scientific article published on 12 January 2017

Shared heritability and functional enrichment across six solid cancers

scientific article published in Nature Communications

Shared heritability and functional enrichment across six solid cancers

Should oncologists be aware in their clinical practice of KRAS molecular analysis?

scientific article

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.

scientific article published on 10 May 2017

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope

scientific article

Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer

scientific article published on 01 January 2017

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis

scientific article published on 15 November 2016

TAS-102 for the treatment of metastatic colorectal cancer.

scientific article

TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply

scientific article published on 01 December 2015

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

scientific article

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

scientific article published on 25 January 2018

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

scientific article published on 19 May 2020

The possible role of chemotherapy in antiangiogenic drug resistance

scientific article published on 25 February 2012

The role of pharmacogenetics in the new ESMO colorectal cancer guidelines.

scientific article published on 23 January 2017

The role of tumor angiogenesis as a therapeutic target in colorectal cancer

scientific article published on 17 January 2018

Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.

scientific article published on 31 August 2016

Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer

scientific article published in January 2006

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

scientific article published on 08 November 2019

Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.

scientific article published on January 2008

VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population.

scientific article

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.

scientific article published on 22 March 2016

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.

scientific article

Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer

scientific article published on 23 December 2008

Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity

scientific article published on 01 May 2007

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.

scientific article published on 10 August 2017

miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis

scientific article published on 16 November 2018

Paulina is supported by:

About Paulina

Help